ArticleBritish journal of cancer2009
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors.
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Negative Effect of Intravenous Antibiotics on Survival in Patients with Triple-Negative Breast Cancer.Cancers · 2025Article
- Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Article
- Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer.Breast (Edinburgh, Scotland) · 2021Article
- Cobalt protoporphyrin IX increases endogenous G-CSF and mobilizes HSC and granulocytes to the blood.EMBO molecular medicine · 2019Article
- Frequency of bloodstream infection in febrile neutropenic patients, experience from a developing country.Annals of medicine and surgery (2012) · 2018Article
- Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Review
- A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Article
- Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment.Pharmaceutical research · 2015Article
- Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.Pharmaceutical research · 2013Article
- Fulminate anaerobic bacteremia after chemotherapy for metastatic breast cancer despite the prophylactic use of GCSF.International medical case reports journal · 2010Article
- Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.British journal of cancer · 2009Article
- Management of chemotherapy-associated febrile neutropenia.British journal of cancer · 2009Article
- Chemotherapy for early-stage breast cancer: a brief history.British journal of cancer · 2009Article
- Impact of effective prevention and management of febrile neutropenia.British journal of cancer · 2009Article
- Prevention of febrile neutropenia: use of prophylactic antibiotics.British journal of cancer · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is good evidence to suggest that dose intensity is important when considering the effectiveness of adjuvant chemotherapy in patients with breast cancer. However, the development of chemotherapy-induced febrile neutropenia can lead to reduction in dose intensity and other treatment modifications, which may negatively affect patient outcomes. Febrile neutropenia can be prevented by the use of primary prophylactic treatment, notably with granulocyte colony-stimulating factors. This practice is supported by international guidelines, all of which recommend that primary prophylaxis with granulocyte colony-stimulating factors should be used with chemotherapy where the risk of febrile neutropenia is 20% or greater.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.